Fred Hutchinson Cancer Research Center

University of Washington Cancer Consortium / SCCA

Seattle, WA

Sorting 23 by

Accepting patients

Optimized Cord Blood Transplant

Optimized Cord Blood Transplantation for the Treatment of High-Risk Hematologic Malignancies in Adults and Pediatrics
  • Cord Blood
  • Phase 2

Accepting patients

RALLY-MF

RALLY-MF: A Phase 1b/2 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of DISC-0974 in Participants with Myelofibrosis or Myelodysplastic Syndrome and AnemiaA Phase 1b/2a Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DISC-0974 in Participants with Myelofibrosis and Anemia
  • Monoclonal Antibody
  • Hemojuvelin (HJV)
  • Randomization
  • Monotherapy
  • Phase 1/2
  • Has results

Accepting patients

BH-30236

A Phase 1/1b Open-Label, Dose Escalation, First-in- Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-leukemic Activity of the Orally Available CDC-Like Kinase (CLK) Inhibitor, BH-30236, in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML) or Higher-Risk Myelodysplastic Syndrome (HR-MDS)
  • CLK Inhibitor
  • Phase 1

Accepting patients

Orca-Q

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
  • Allogeneic Stem Cell Transplant
  • Phase 1

Accepting patients

AZTOUND

A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
  • DNMT1 Inhibitor
  • Phase 2/3
  • Has results

Accepting patients

DR. DREAM

Decoy-Resistant Interleukin-18 (DR-18) for Relapse or Pre-emptive Treatment of Measurable Residual Disease After Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome (DR. DREAM)
  • Interleukin 18 (IL-18)
  • Phase 1

Accepting patients

MyeloMATCH Master Protocol

Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials
  • Genetic Sequencing
  • Phase 2

Accepting patients

VIP943

An Open-label, Multicenter Phase 1 Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity, Pharmacokinetics, and Pharmacodynamics of VIP943 Monotherapy in Subjects With Advanced CD123+ Hematologic Malignancies
  • Kinesin Spindle Protein (KSP) Inhibitor
  • Antibody Drug Conjugate (ADC)
  • CD123
  • Phase 1

Accepting patients

Interferon-γ With Donor Leukocyte Infusion

A Phase 2 Trial of Interferon-γ (IFN-γ) in Combination With Donor Leukocyte Infusion (DLI) to Treat Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) After Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)
  • Immunotherapy
  • Donor Lymphocyte Infusion (DLI)
  • Phase 2

Accepting patients

Safety Study of Cord Blood Units

Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation
  • Allogeneic Stem Cell Transplant
  • Phase 2